Our results show the potential of targeting DR5 expressing tumour cells, such as OVCAR-3 with NK cells engineered to express a potent and specific DR5 TRAIL variant, which maximizes both Granzyme mediated killing as well as apoptosis via the death receptor pathway. Here, TNFRSF10B is linked to neoplasm.